Efficacy and safety of Uthever® nicotinamide mononucleotide supplementation in middle-aged and older adults: a randomized, double-blind, placebo-controlled trial
Published 2022
Study Design
- Population
- 66 healthy adults aged 40–65 years
- Design
- Randomized, double-blind, placebo-controlled, parallel-group study
- Dosage
- 300 mg/day NMN (Uthever®)
- Duration
- 60 days
Citation
Frontiers in Aging (2022).
Authors: Huang, H., Chen, H., Zhou, J., Liu, X., Zhang, S.
Affiliation: Effepharm (Shanghai) Co., Ltd., Shanghai, China
Plain takeaway
Uthever® NMN at 300 mg/day safely increased NAD+ and improved self-reported health over 60 days in middle-aged adults.
Study context
Hypothesis: Daily supplementation with 300 mg NMN (Uthever®) will increase NAD+/NADH levels and improve physiological markers of well-being in healthy adults aged 40–65 years.
Objective: To assess the safety and NAD+-boosting efficacy of Uthever® NMN at 300 mg/day for 60 days in healthy middle-aged adults.
Abstract
This 60-day randomized, double-blind, placebo-controlled study in 66 adults aged 40–65 found that 300 mg/day NMN (Uthever®) significantly raised NAD+ levels and improved well-being compared to placebo without adverse effects.
Methods & Controls
Participants were randomized to receive either 300 mg NMN or placebo daily for 60 days. NAD+/NADH levels, SF-36 quality-of-life score, HOMA-IR, and safety parameters were measured at baseline, 30 days, and 60 days.
Controls: Matching placebo capsules identical in appearance and administered once daily.
Key outcomes
- Serum NAD+/NADH increased by 11.3% at day 30 and 38% at day 60 in NMN group vs ~14% in placebo (p < 0.05).
- SF-36 score improved by 6.5% in NMN vs 3.4% in placebo after 60 days.
- HOMA-IR rose in placebo group but not in NMN group.
- No serious adverse events observed.
Summary & Interpretation
The trial demonstrates NMN’s NAD+-boosting potential and safety at 300 mg/day. While encouraging, longer and multi-dose studies are needed to confirm broader metabolic or longevity outcomes.